NCT01461759 is a Phase 2 clinical trial of Doctaxel in Advanced or Recurrent Endometrial Cancer, sponsored by Asan Medical Center.

Who is sponsoring NCT01461759?

NCT01461759 is sponsored by Asan Medical Center.

What drugs are being tested in NCT01461759?

Interventions in NCT01461759: Doctaxel, Cisplatin.

What condition does NCT01461759 study?

NCT01461759 studies Advanced or Recurrent Endometrial Cancer.

Is NCT01461759 still recruiting?

NCT01461759 is currently status unknown. Last updated 27 May 2017.

Last reviewed 2017-05-27 · How we verify

NCT01461759

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer

Status unknown Phase 2 Last updated 27 May 2017

What this trial tests

Phase 2 trial testing Doctaxel in Advanced or Recurrent Endometrial Cancer in 59 participants. Status unknown.

Timeline

1 October 2011

Primary endpoint
1 December 2017

1 December 2017

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	1 October 2011
Primary completion	1 December 2017
Estimated completion	1 December 2017
Sites	1 location across South Korea

Drugs / interventions tested

Doctaxel — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Advanced or Recurrent Endometrial Cancer — all drugs for Advanced or Recurrent Endometrial Cancer →

Sponsor

Asan Medical Center

Who can join

Adults 20 to 75, female only, with Advanced or Recurrent Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response rate
Time frame: 3 months after completion of study treatment

Sponsor's own description

The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Asian Society of Gynecologic Oncology International Workshop 2018.
Kong TW, Ryu HS, Kim SC, Enomoto T, et al · · 2019 · cited 10× · PMID 30740961 · DOI 10.3802/jgo.2019.30.e39

Verify or expand the search:

Other recruiting trials for Advanced or Recurrent Endometrial Cancer

Currently open trials in the same condition.

NCT06746116 — A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Ol · Phase 3 · active not recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01461759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 27 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01461759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing